Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Igc Pharma Inc (IGC)

Igc Pharma Inc (IGC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 31,761
  • Shares Outstanding, K 92,868
  • Annual Sales, $ 1,270 K
  • Annual Income, $ -7,120 K
  • EBIT $ -8 M
  • EBITDA $ -7 M
  • 60-Month Beta 0.24
  • Price/Sales 21.77
  • Price/Cash Flow N/A
  • Price/Book 3.42
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.07
  • Most Recent Earnings $-0.02 on 11/14/25
  • Next Earnings Date 02/13/26
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Options Overview Details

View History
  • Implied Volatility 502.15% (-20.98%)
  • Historical Volatility 56.41%
  • IV Percentile 69%
  • IV Rank 51.44%
  • IV High 843.35% on 02/19/25
  • IV Low 140.73% on 08/18/25
  • Expected Move (DTE 8) 0.0425 (13.12%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 507
  • Volume Avg (30-Day) 98
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 9,215
  • Open Int (30-Day) 11,092
  • Expected Range 0.2814 to 0.3664

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.02
  • Number of Estimates 1
  • High Estimate -0.02
  • Low Estimate -0.02
  • Prior Year -0.02
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2839 +15.50%
on 12/08/25
0.3868 -15.23%
on 11/12/25
-0.0588 (-15.21%)
since 11/11/25
3-Month
0.2839 +15.50%
on 12/08/25
0.4508 -27.26%
on 11/03/25
-0.0760 (-18.82%)
since 09/11/25
52-Week
0.2525 +29.86%
on 04/07/25
0.4985 -34.22%
on 08/27/25
-0.0573 (-14.88%)
since 12/11/24

Most Recent Stories

More News
IGC Pharma Subsidiary Signs Asset Sale Agreement

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. IGC Pharma...

IGC : 0.3279 (-4.12%)
IGC Pharma Welcomes Strategic Investment from Advisors

POTOMAC, MARYLAND / ACCESS Newswire / April 24, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announced that the Company's recently appointed advisors entered into a Share...

IGC : 0.3279 (-4.12%)
IGC Pharma Welcomes Industry Leaders to Advisory Board, Supporting Alzheimer's Innovation and AI-Driven Programs

Industry Veterans Bring Deep Strategic Experience to Guide Alzheimer's Clinical Expansion and Commercial Strategy

IGC : 0.3279 (-4.12%)
IGC Pharma Expands CALMA Alzheimer's Phase 2 Trial with Prestigious Research Site at Butler Hospital's Memory and Aging Program

POTOMAC, MARYLAND / ACCESS Newswire / April 8, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") today announced the expansion of its ongoing Phase 2 CALMA clinical trial with...

IGC : 0.3279 (-4.12%)
IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish Health

POTOMAC, MARYLAND / ACCESS Newswire / April 1, 2025 / IGC Pharma, Inc. (NYSE American:IGC) today announced the expansion of its Phase 2 clinical trial, CALMA, evaluating IGC-AD1 for the treatment of agitation...

IGC : 0.3279 (-4.12%)
IGC Pharma's Phase 2 Clinical Trial Interim Data Demonstrates Significant Reduction in Sleep Disturbances

- IGC-AD1 Could Offer Safer Alternative to Existing Sleep Medications for Alzheimer's -

IGC : 0.3279 (-4.12%)
IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Canadian Hamilton Health Sciences

POTOMAC, MD / ACCESS Newswire / March 20, 2025 / IGC Pharma, Inc. ("IGC", or the "Company") (NYSE American:IGC) today announced the expansion of its ongoing Phase 2 CALMA trial for IGC-AD1 with the addition...

IGC : 0.3279 (-4.12%)
IGC Pharma Expands CALMA Trial with Addition of BayCare Health System in Florida

POTOMAC, MARYLAND / ACCESS Newswire / March 17, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") today announced the addition of a new trial site at BayCare's St. Anthony's Hospital...

IGC : 0.3279 (-4.12%)
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock. Raising P/T to $4.25"

POTOMAC, MARYLAND / ACCESS Newswire / March 12, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC) announces that Ascendiant Capital Markets has issued a coverage report...

IGC : 0.3279 (-4.12%)
IGC Pharma Announces Equity Analyst Update by Alliance Global Partners (AGP) about the “Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results”

POTOMAC, MARYLAND / ACCESS Newswire / March 10, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC) announces that Alliance Global Partners (AGP) has issued an analyst update...

IGC : 0.3279 (-4.12%)

Business Summary

IGC Pharma Inc. develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. IGC Pharma Inc., formerly known as India Globalization Capital Inc., is based in POTOMAC, Md....

See More

Key Turning Points

3rd Resistance Point 0.4273
2nd Resistance Point 0.3927
1st Resistance Point 0.3673
Last Price 0.3279
1st Support Level 0.3073
2nd Support Level 0.2727
3rd Support Level 0.2473

See More

52-Week High 0.4985
Fibonacci 61.8% 0.4045
Fibonacci 50% 0.3755
Fibonacci 38.2% 0.3465
Last Price 0.3279
52-Week Low 0.2525

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar